Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction
Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1997-03, Vol.79 (6), p.727-732 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 732 |
|---|---|
| container_issue | 6 |
| container_start_page | 727 |
| container_title | The American journal of cardiology |
| container_volume | 79 |
| creator | Bär, F W Meyer, J Vermeer, F Michels, R Charbonnier, B Haerten, K Spiecker, M Macaya, C Hanssen, M Heras, M Boland, J P Morice, M C Dunn, F G Uebis, R Hamm, C Ayzenberg, O Strupp, G Withagen, A J Klein, W Windeler, J Hopkins, G Barth, H von Fisenne, M J |
| description | Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78893811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78893811</sourcerecordid><originalsourceid>FETCH-LOGICAL-p539-a45e70ae591488bbc106ad7c225c3ffbb3c9b752359295325d9fba0d831ae8f33</originalsourceid><addsrcrecordid>eNpVkM1qwzAQhH1oSdO0j1DQqTcH2Ypi6RhCmgYSerDvZvVHVGzLlSxKXqdPWkNMf07LDLPfsHuTzDHGecqzFb9L7kN4H2WW0fUsmXFcYLri8-Rr69oevA2uQ86gAD72DQSNoFMImkFfle0QyDho1F6cBK8sNKNnwMvBum6Jyl25OaFyiOqC9t7Ffomqs56McXkXves1-rTDGZX_OjZ_O06_9MMP_SG5NdAE_TjNRVK97Krta3p82x-2m2PaU8JTWFFdYNB0PJcxIWSG16AKmedUEmOEIJKLguaE8pxTklPFjQCsGMlAM0PIInm-YnvvPqIOQ93aIHXTQKddDHXBGCcsy8bg0xSMotWq7r1twV_q6afkG7nzdIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78893811</pqid></control><display><type>article</type><title>Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bär, F W ; Meyer, J ; Vermeer, F ; Michels, R ; Charbonnier, B ; Haerten, K ; Spiecker, M ; Macaya, C ; Hanssen, M ; Heras, M ; Boland, J P ; Morice, M C ; Dunn, F G ; Uebis, R ; Hamm, C ; Ayzenberg, O ; Strupp, G ; Withagen, A J ; Klein, W ; Windeler, J ; Hopkins, G ; Barth, H ; von Fisenne, M J</creator><creatorcontrib>Bär, F W ; Meyer, J ; Vermeer, F ; Michels, R ; Charbonnier, B ; Haerten, K ; Spiecker, M ; Macaya, C ; Hanssen, M ; Heras, M ; Boland, J P ; Morice, M C ; Dunn, F G ; Uebis, R ; Hamm, C ; Ayzenberg, O ; Strupp, G ; Withagen, A J ; Klein, W ; Windeler, J ; Hopkins, G ; Barth, H ; von Fisenne, M J</creatorcontrib><description>Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase.</description><identifier>ISSN: 0002-9149</identifier><identifier>PMID: 9070549</identifier><language>eng</language><publisher>United States</publisher><subject><![CDATA[Aged ; Double-Blind Method ; Europe - epidemiology ; Female ; Fibrinolytic Agents - administration & dosage ; Humans ; Male ; Middle Aged ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Plasminogen Activators - administration & dosage ; Recombinant Proteins - administration & dosage ; Recurrence ; Thrombolytic Therapy - methods ; Thrombolytic Therapy - statistics & numerical data ; Tissue Plasminogen Activator - administration & dosage ; Treatment Outcome ; Urokinase-Type Plasminogen Activator - administration & dosage]]></subject><ispartof>The American journal of cardiology, 1997-03, Vol.79 (6), p.727-732</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9070549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bär, F W</creatorcontrib><creatorcontrib>Meyer, J</creatorcontrib><creatorcontrib>Vermeer, F</creatorcontrib><creatorcontrib>Michels, R</creatorcontrib><creatorcontrib>Charbonnier, B</creatorcontrib><creatorcontrib>Haerten, K</creatorcontrib><creatorcontrib>Spiecker, M</creatorcontrib><creatorcontrib>Macaya, C</creatorcontrib><creatorcontrib>Hanssen, M</creatorcontrib><creatorcontrib>Heras, M</creatorcontrib><creatorcontrib>Boland, J P</creatorcontrib><creatorcontrib>Morice, M C</creatorcontrib><creatorcontrib>Dunn, F G</creatorcontrib><creatorcontrib>Uebis, R</creatorcontrib><creatorcontrib>Hamm, C</creatorcontrib><creatorcontrib>Ayzenberg, O</creatorcontrib><creatorcontrib>Strupp, G</creatorcontrib><creatorcontrib>Withagen, A J</creatorcontrib><creatorcontrib>Klein, W</creatorcontrib><creatorcontrib>Windeler, J</creatorcontrib><creatorcontrib>Hopkins, G</creatorcontrib><creatorcontrib>Barth, H</creatorcontrib><creatorcontrib>von Fisenne, M J</creatorcontrib><title>Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase.</description><subject>Aged</subject><subject>Double-Blind Method</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Fibrinolytic Agents - administration & dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Plasminogen Activators - administration & dosage</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recurrence</subject><subject>Thrombolytic Therapy - methods</subject><subject>Thrombolytic Therapy - statistics & numerical data</subject><subject>Tissue Plasminogen Activator - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Urokinase-Type Plasminogen Activator - administration & dosage</subject><issn>0002-9149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkM1qwzAQhH1oSdO0j1DQqTcH2Ypi6RhCmgYSerDvZvVHVGzLlSxKXqdPWkNMf07LDLPfsHuTzDHGecqzFb9L7kN4H2WW0fUsmXFcYLri8-Rr69oevA2uQ86gAD72DQSNoFMImkFfle0QyDho1F6cBK8sNKNnwMvBum6Jyl25OaFyiOqC9t7Ffomqs56McXkXves1-rTDGZX_OjZ_O06_9MMP_SG5NdAE_TjNRVK97Krta3p82x-2m2PaU8JTWFFdYNB0PJcxIWSG16AKmedUEmOEIJKLguaE8pxTklPFjQCsGMlAM0PIInm-YnvvPqIOQ93aIHXTQKddDHXBGCcsy8bg0xSMotWq7r1twV_q6afkG7nzdIA</recordid><startdate>19970315</startdate><enddate>19970315</enddate><creator>Bär, F W</creator><creator>Meyer, J</creator><creator>Vermeer, F</creator><creator>Michels, R</creator><creator>Charbonnier, B</creator><creator>Haerten, K</creator><creator>Spiecker, M</creator><creator>Macaya, C</creator><creator>Hanssen, M</creator><creator>Heras, M</creator><creator>Boland, J P</creator><creator>Morice, M C</creator><creator>Dunn, F G</creator><creator>Uebis, R</creator><creator>Hamm, C</creator><creator>Ayzenberg, O</creator><creator>Strupp, G</creator><creator>Withagen, A J</creator><creator>Klein, W</creator><creator>Windeler, J</creator><creator>Hopkins, G</creator><creator>Barth, H</creator><creator>von Fisenne, M J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970315</creationdate><title>Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction</title><author>Bär, F W ; Meyer, J ; Vermeer, F ; Michels, R ; Charbonnier, B ; Haerten, K ; Spiecker, M ; Macaya, C ; Hanssen, M ; Heras, M ; Boland, J P ; Morice, M C ; Dunn, F G ; Uebis, R ; Hamm, C ; Ayzenberg, O ; Strupp, G ; Withagen, A J ; Klein, W ; Windeler, J ; Hopkins, G ; Barth, H ; von Fisenne, M J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p539-a45e70ae591488bbc106ad7c225c3ffbb3c9b752359295325d9fba0d831ae8f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Double-Blind Method</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Fibrinolytic Agents - administration & dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Plasminogen Activators - administration & dosage</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recurrence</topic><topic>Thrombolytic Therapy - methods</topic><topic>Thrombolytic Therapy - statistics & numerical data</topic><topic>Tissue Plasminogen Activator - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Urokinase-Type Plasminogen Activator - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bär, F W</creatorcontrib><creatorcontrib>Meyer, J</creatorcontrib><creatorcontrib>Vermeer, F</creatorcontrib><creatorcontrib>Michels, R</creatorcontrib><creatorcontrib>Charbonnier, B</creatorcontrib><creatorcontrib>Haerten, K</creatorcontrib><creatorcontrib>Spiecker, M</creatorcontrib><creatorcontrib>Macaya, C</creatorcontrib><creatorcontrib>Hanssen, M</creatorcontrib><creatorcontrib>Heras, M</creatorcontrib><creatorcontrib>Boland, J P</creatorcontrib><creatorcontrib>Morice, M C</creatorcontrib><creatorcontrib>Dunn, F G</creatorcontrib><creatorcontrib>Uebis, R</creatorcontrib><creatorcontrib>Hamm, C</creatorcontrib><creatorcontrib>Ayzenberg, O</creatorcontrib><creatorcontrib>Strupp, G</creatorcontrib><creatorcontrib>Withagen, A J</creatorcontrib><creatorcontrib>Klein, W</creatorcontrib><creatorcontrib>Windeler, J</creatorcontrib><creatorcontrib>Hopkins, G</creatorcontrib><creatorcontrib>Barth, H</creatorcontrib><creatorcontrib>von Fisenne, M J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bär, F W</au><au>Meyer, J</au><au>Vermeer, F</au><au>Michels, R</au><au>Charbonnier, B</au><au>Haerten, K</au><au>Spiecker, M</au><au>Macaya, C</au><au>Hanssen, M</au><au>Heras, M</au><au>Boland, J P</au><au>Morice, M C</au><au>Dunn, F G</au><au>Uebis, R</au><au>Hamm, C</au><au>Ayzenberg, O</au><au>Strupp, G</au><au>Withagen, A J</au><au>Klein, W</au><au>Windeler, J</au><au>Hopkins, G</au><au>Barth, H</au><au>von Fisenne, M J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1997-03-15</date><risdate>1997</risdate><volume>79</volume><issue>6</issue><spage>727</spage><epage>732</epage><pages>727-732</pages><issn>0002-9149</issn><abstract>Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase.</abstract><cop>United States</cop><pmid>9070549</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1997-03, Vol.79 (6), p.727-732 |
| issn | 0002-9149 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78893811 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Double-Blind Method Europe - epidemiology Female Fibrinolytic Agents - administration & dosage Humans Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Plasminogen Activators - administration & dosage Recombinant Proteins - administration & dosage Recurrence Thrombolytic Therapy - methods Thrombolytic Therapy - statistics & numerical data Tissue Plasminogen Activator - administration & dosage Treatment Outcome Urokinase-Type Plasminogen Activator - administration & dosage |
| title | Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A43%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20saruplase%20and%20alteplase%20in%20acute%20myocardial%20infarction.%20SESAM%20Study%20Group.%20The%20Study%20in%20Europe%20with%20Saruplase%20and%20Alteplase%20in%20Myocardial%20Infarction&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=B%C3%A4r,%20F%20W&rft.date=1997-03-15&rft.volume=79&rft.issue=6&rft.spage=727&rft.epage=732&rft.pages=727-732&rft.issn=0002-9149&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E78893811%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78893811&rft_id=info:pmid/9070549&rfr_iscdi=true |